Last $12.24 USD
Change Today -0.35 / -2.78%
Volume 1.7M
IRWD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

ironwood pharmaceuticals inc (IRWD) Snapshot

Open
$12.55
Previous Close
$12.59
Day High
$12.82
Day Low
$12.12
52 Week High
07/30/14 - $15.95
52 Week Low
11/13/13 - $8.95
Market Cap
1.7B
Average Volume 10 Days
1.4M
EPS TTM
$-1.76
Shares Outstanding
120.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IRONWOOD PHARMACEUTICALS INC (IRWD)

ironwood pharmaceuticals inc (IRWD) Related Businessweek News

No Related Businessweek News Found

ironwood pharmaceuticals inc (IRWD) Details

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company’s lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

534 Employees
Last Reported Date: 02/7/14
Founded in 1998

ironwood pharmaceuticals inc (IRWD) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $100.0K
Chief Operating Officer and Senior Vice Presi...
Total Annual Compensation: $360.9K
Chief Scientific Officer, President of Resear...
Total Annual Compensation: $376.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $366.6K
Compensation as of Fiscal Year 2013.

ironwood pharmaceuticals inc (IRWD) Key Developments

Ironwood Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 08:00 AM

Ironwood Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Peter M. Hecht, Co-Founder, Chief Executive Officer and Director.

Ironwood Pharmaceuticals, Inc. Announces Management Changes

Ironwood Pharmaceuticals, Inc. announced the appointment of Thomas Graney as chief financial officer (CFO) and senior vice president of finance and corporate strategy, and the appointment of Lisa Adler as senior vice president of corporate communications. Prior to joining the company, Mr. Graney served as worldwide vice president of finance and CFO of Ethicon, a global leader in surgical medical devices and a Johnson & Johnson (J&J) company. Ms. Adler previously served as vice president of corporate communications for Millennium: The Takeda Oncology Company. Michael Higgins, who was CFO and chief operating officer (COO) of the company, has decided to leave the company but plans to remain as COO through December 2014 to ensure a smooth transition.

Ironwood Pharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Ironwood Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $6,840,000 against $9,663,000 a year ago. Loss from operations was $55,119,000 against $59,880,000 a year ago. Net loss was $60,537,000 against $65,149,000 a year ago. Net loss per basic and diluted share was $0.44 against $0.57 a year ago. The company used approximately $36 million of cash for operations during the second quarter of 2014, as compared to approximately $58 million in the first quarter of 2014. For the six months, the company reported revenue of $21,445,000 against $12,918,000 a year ago. Loss from operations was $99,506,000 against $148,713,000 a year ago. Net loss was $109,983,000 against $159,051,000 a year ago. Net loss per basic and diluted share was $0.82 against $1.44 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRWD:US $12.24 USD -0.35

IRWD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $5.05 USD +0.045
Nektar Therapeutics $13.59 USD +0.06
Progenics Pharmaceuticals Inc $5.20 USD +0.05
Sucampo Pharmaceuticals Inc $6.63 USD +0.08
Theravance Inc $18.45 USD -0.01
View Industry Companies
 

Industry Analysis

IRWD

Industry Average

Valuation IRWD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 55.4x
Price/Book 12.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRONWOOD PHARMACEUTICALS INC, please visit www.ironwoodpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.